AVIR - Atea Pharmaceuticals, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

AVIR

ATEA PHARMACEUTICALS, INC.

NASDAQ

$5.05

▼ DOWN 1.55% (-0.08)

KEY STATISTICS

Market Cap$410.54 M

52w High$6.45

52w Low$2.84

Dividend Yield—

Frequency—

P/E-2.39

Volume29.74K

Shares Out.80.03M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jean-Pierre Sommadossi

COMPENSATION 2026

Salary$703,490

Stock Awards$1,315,800

Incentive Plan Pay$422,094

All Other Comp.$0

Total$3,403,752

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 30, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$7.00

Target Low$7.00

Target Median$7.00

Target Consensus$7.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$50.45M

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

64.22%

HOLDERS

176

TOP 8 OF 176 · RANKED BY POSITION SIZE

Bml Capital Management, LLC

7.5M sh

$26.74M

Tang Capital Management LLC

Bain Capital Life Sciences Investors, LLC

2.5M sh

$7.21M

Acadian Asset Management LLC

2.0M sh

$9.46M

PRICE

$5.05 ▼ DOWN 1.55% (−$0.08)

About Atea Pharmaceuticals, Inc.

https://www.ateapharma.com ↗

Atea Pharmaceuticals is a Boston-based clinical-stage biopharma developing antiviral therapeutics like AT-527 for COVID-19 and other candidates targeting viral infections such as dengue, HCV, Zika, and yellow fever.

INDUSTRY

Biotechnology

A PRODUCT ATEA PHARMACEUTICALS, INC. IS KNOWN FOR

Bemnifosbuvir and Ruzasvir (combination regimen)

Atea Pharmaceuticals is developing an investigational all-oral, fixed-dose combination of bemnifosbuvir and ruzasvir for HCV, currently in Phase 3 trials with results expected in 2026, aiming to provide a potentially best-in-class treatment.

COMPETITORS

COMPETITOR

Atea Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

OTHER · DECEMBER 2025

Atea Pharmaceuticals Completes Enrollment for Pivotal Phase 3 Hepatitis C Trial, Setting Stage for Mid-2026 Data Release

Atea Pharmaceuticals announced the completion of patient enrollment for its C-BEYOND Phase 3 trial in North America, a critical milestone for its lead Hepatitis C virus (HCV) treatment regimen of bemnifosbuvir and ruzasvir. This achievement was a key inflection point for the company, solidifying the timeline for much-anticipated topline results expected in mid-2026 and increasing investor confidence in the execution of its late-stage clinical program.

RESTRUCTURING · Q1 2025 · COMPLETED

Atea Pharmaceuticals Implements Strategic Restructuring with 25% Workforce Reduction to Prioritize Late-Stage Hepatitis C Program

In a significant strategic move to streamline operations and conserve capital, Atea Pharmaceuticals announced a reduction of its workforce by approximately 25% during the first quarter of 2025. This decision is part of a broader cost-cutting initiative aimed at enhancing efficiency as the company advances its lead Hepatitis C virus (HCV) treatment into global Phase 3 trials.